Tabalumab Explained

Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies.^{[1] [2]} Tabalumab was developed by Eli Lilly and Company.

A phase III clinical trial for rheumatoid arthritis was halted in Feb 2013.^[3] In September 2014, a second phase III trial focussing on treating systemic lupus erythematosus, was terminated early as the study failed to meet its primary endpoint.^[4]

References

1. Web site: Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab. American Medical Association.
2. Web site: BAFF Antibody: Tabalumab, LY2127399 . Lilly USA, LLC . https://web.archive.org/web/20130812045007/http://www.lillyoncologypipeline.com/Pages/baff-antibody.aspx . 12 August 2013 .
3. Web site: Press Release Archive - Press Release Archives.
4. Web site: Lilly Halts Tabalumab Development for Lupus. 2 October 2014.

Now dropped by Lilly due to lack of efficacy.